Trial record 1 of 1 for:    Immunotherapy with hLL1-DOX
Previous Study | Return to List | Next Study

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01585688
Recruitment Status : Unknown
Verified September 2015 by Immunomedics, Inc..
Recruitment status was:  Active, not recruiting
First Posted : April 26, 2012
Last Update Posted : September 7, 2015
Information provided by (Responsible Party):
Immunomedics, Inc.

April 23, 2012
April 26, 2012
September 7, 2015
August 2012
November 2016   (Final data collection date for primary outcome measure)
  • Safety [ Time Frame: during treatment and the change at 4, 8 & 12 weeks after treatment ]
    Safety will be measured by physical examinations and hematology and chemistry blood tests. Cardiac safety will be done using MUGA scans or echocardiograms. These assessments will be done routinely during treatment and again 4, 8 and 12 weeks after treatment. Long term safety will be assessed every 3 months after that for up to 2 years.
  • Efficacy [ Time Frame: During treatment and the changes at 4, 8 and 12 weeks after treatment ]
    Efficacy will be assessed using CT scans for NHL patients and CT scans and hematology labs for CLL patients. At the beginning of a complete response a repeat bone marrow biopsy may be required. These assessments will be done 8 weeks after the start of treatment and again 10-12 weeks later at the end of treatment. The tests will be repeated at 4, 8 and 12 weeks after treatment and then every 3 months for up to 2 years.
Same as current
Complete list of historical versions of study NCT01585688 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.
Patients receive hLL1-DOX at one of 4 dose levels administered on Days 1, 4, 8 and 11 of 21-day treatment cycles which are continued in the absence of progression or unacceptable toxicity up to a total of 8 cycles. After treatment, follow-up will be done at 4, 8 and 12 weeks post-treatment and will continue to be done every 3 months for up to 2 years.
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukemia
Drug: hLL1-DOX (IMMU-115)
hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
Other Name: IMMU-115
Experimental: hLL1-DOX
Intervention: Drug: hLL1-DOX (IMMU-115)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
February 2017
November 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female, age ≥ 18 years
  • Able to provide signed, informed consent
  • Histologically confirmed diagnosis of recurrent B-cell non-Hodgkin's lymphoma (any histology by WHO criteria) or recurrent chronic lymphocytic leukemia (by NCI criteria) (Reference Appendix C)
  • Received at least one prior treatment with standard therapy (previous antibody therapy is acceptable)
  • Measurable disease at least one lesion ≥ 1.5 cm for NHL and ALC > 5,000 for CLL
  • Adequate performance status (≥ 70 Karnofsky scale) with an estimated life expectancy of at least 6 months

    --Documented negative hepatitis B screen, per NCCN guidelines (hepatitis B surface antigen/antibodies, core antigen/antibodies, hepatitis B e-antigen)

  • At least 12 weeks beyond stem cell transplant and 4 weeks beyond chemotherapy or immunotherapy, major surgery, other experimental treatments, or radiation therapy to the index lesions, and with all acute toxicities from prior therapy resolved to less than Grade 2 toxicity by NCI CTC version 4.0
  • Laboratory parameters:

Adequate hematology without ongoing transfusional support Hemoglobin >/= 10 g/dL Absolute neutrophil count >/= 1.5 x 10 9/L Platelets >/= 75 x 10 9/L Creatinine and bilirubin </= 1.5 x IULN AST and ALT </= 2.5 x IULN

-Adequate cardiac function (MUGA scan or 2-D ECHO with LVEF ≥ 55%, EKG with no medically relevant arrhythmia uncontrolled on medications)

Exclusion Criteria:

  • -Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
  • Women of childbearing potential and fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study until at least 12 weeks after the last milatuzumab infusion
  • Prior therapy with other human or humanized monoclonal antibodies, unless HAHA tested and negative
  • Prior treatment with trastuzumab
  • Bulky disease by CT, defined as any single mass > 10 cm in its greatest diameter
  • Known HIV positive or active hepatitis B or C, or presence of hepatitis B surface antigens or presence of hepatitis C antibody
  • New York Heart Classification III or IV heart disease (see Appendix G). Other severe cardiovascular or cardiopulmonary disease, including COPD
  • Baseline BNP > 2 x IULN
  • Patients with uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities will be excluded
  • Patients with recent (≤ 6 months) cardiac angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias will be excluded
  • Known autoimmune disease or presence of autoimmune phenomena
  • At least 7 days beyond any infection requiring intravenous antibiotic use (Oral antibiotics may be administered prophylactically as clinically indicated)
  • Systemic corticosteroids within 2 weeks, except low dose regimens (prednisone, ≤ 20 mg/day, or equivalent) which may continue if unchanged
  • Substance abuse or other concurrent medical or psychiatric conditions that, in the Investigator's opinion, could confound study interpretation or affect the patient's ability to tolerate or complete the study
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Immunomedics, Inc.
Immunomedics, Inc.
Not Provided
Study Director: Pius P Maliakal, PhD Immunomedics, Inc.
Study Chair: Francois Wilhelm, MD,PhD Immunomedics, Inc.
Immunomedics, Inc.
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP